Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 1636 • ACR Convergence 2021
Pediatric Rheumatologists’ Perspectives on Diagnosis, Treatment and Outcomes of Sjögren Syndrome in Children and Adolescents
Rachel Randell¹, Sara Stern², Heather Van Mater¹, Scott Lieberman³ and Matthew Basiaga⁴, ¹Duke University, Durham, NC, ²University of Utah, Salt Lake City, UT, ³University of Iowa, Iowa City, IA, ⁴Mayo Clinic, Inver Grove Heights, MN
Background/Purpose: Sjögren syndrome in children and adolescents often presents differently from adult disease, with many pediatric patients failing to meet adult criteria. Additionally, treatment and…
Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
Abstract Number: 0771 • ACR Convergence 2021
Race, Ethnicity and Patient-Reported Outcomes in Childhood-Onset Systemic Lupus Erythematosus
R. Ezequiel Borgia¹, Matthew Gurka², Stephanie Filipp², Melissa Elder³, Michelle Cardel² and Natalie Shiff⁴, ¹Department of Pediatrics, University of Florida, Gainesville, FL, USA. Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, ²Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, ³Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Florida, Gainesville, FL, ⁴University of Saskatchewan, Department of Community Health and Epidemiology, Saskatoon, SK, Canada. Janssen Scientific Affairs, LLC, Horsham, PA., Gainesville, FL
Background/Purpose: The association of race/ethnicity with childhood-onset systemic lupus erythematosus (cSLE) outcomes has been well described, with non-White individuals experiencing a more severe disease phenotype…
Abstract Number: 0979 • ACR Convergence 2021
Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations
Jonathan Li¹, Emily Mirizio¹, Katherine Buhler², May Choi³, Haiyan Hou², Giffin Werner¹, Anwesha Sanyal¹, Kaila Schollaert-Fitch¹, Marvin Fritzler² and Kathryn Torok¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Pediatric scleroderma encompasses juvenile onset localized scleroderma (jLS) and juvenile onset systemic sclerosis (jSSc), both of which present with varied cutaneous fibrosis and systemic…
Abstract Number: 1617 • ACR Convergence 2021
Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
Maitry Sonagra¹, Jeremy Jones², Mackenzie McGill³ and Sabrina Gmuca³, ¹Seattle Children's Hospital, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Adverse childhood experiences (ACEs) serve as stressors that can have negative, lasting effects on health and wellbeing. While there has been increasing evidence to…
Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Eric Kok, Martha Curry, Andrea Ramirez, Eyal Muscal and Marietta DeGuzman, Baylor College of Medicine, Houston, TX
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…
Abstract Number: 0258 • ACR Convergence 2021
Developing Electronic Health Record Algorithms That Accurately Identify Patients with Juvenile Idiopathic Arthritis
Hannah Peterson¹, April Barnado² and Anna Patrick², ¹Lipscomb University College of Pharmacy, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Electronic Health Records (EHRs) store nearly all clinical data in one central location providing increased accessibility, accuracy, and security. At our institution, the Synthetic…
Abstract Number: 0772 • ACR Convergence 2021
Pediatric Craniofacial Scleroderma: Assessing Handheld 3D Stereophotogrammetric Imaging Feasibility and Reliability
Daniel Glaser¹, Kaila Schollaert-Fitch², Christopher Liu¹, Jesse Goldstein¹ and Kathryn Torok², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Craniofacial scleroderma (Cf-LS), also known as Parry-Romberg Syndrome or scleroderma en coup de sabre, is a subtype of localized scleroderma (morphea). Diagnosis and monitoring…
Abstract Number: 1007 • ACR Convergence 2021
Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
Jacob Spitznagle¹, Akadia Kacha-Ochana², Joan Cook-Mills³, Amer Khojah², Gabrielle Morgan⁴ and Lauren Pachman⁵, ¹Hospital for Special Surgery, New York, NY, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Indiana University School of Medicine, Departments of Pediatrics and Microbiology & Immunology, Indianapolis, IN, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic vasculopathy associated with metabolic derangements and possible increased risk for premature atherosclerosis. Oxidation of low-density lipoprotein (LDL) in…
Abstract Number: 1618 • ACR Convergence 2021
Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib
Kader Cetin Gedik¹, Grace Materne², Ana Ortega-Villa³, Gina Montealegre Sanchez⁴, Adam Reinhardt⁵, Paul Brogan⁶, Yackov Berkun⁷, Sara Murias⁸, Maria Robles⁹, Susanne Schalm¹⁰, Adriana Almeida de Jesus¹¹ and Raphaela Goldbach-Mansky¹², ¹Translational Autoinflammatory Diseases Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Diseases Section, NIAID/NIH, Bethesda, TN, ³Biostatistics Research Branch, Division of Clinical Research, NIAID/NIH, Bethesda, ⁴NIAID/NIH, Bethesda, MD, ⁵Boys Town National Research Hospital, Omaha, NE, ⁶UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁷Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Eskenazi Health Center, IndianaPolis, IN, ¹⁰Rheumatologie im Zentrum, Munich, Germany, ¹¹TADS/NIAID/NIH, Silver Spring, MD, ¹²NIH/NIAID, Potomac, MD
Background/Purpose: Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures /proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to treatment with baricitinib but require higher exposure…
Abstract Number: 1640 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions
Claire Butters¹, Deepthi Abraham², Heidi Facey-Thomas¹, Debbie Abrahams¹, Ayodele Faleye³, Helena Rabie², Christiaan Scott⁴, Liesl Zühlke⁵ and Kate Webb⁶, ¹Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ²Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa, ³Lagos state university teaching hospital Ikeja, Lagos, Nigeria, ⁴University of Cape Town, Faculty of Health Science, Cape Town, South Africa, ⁵Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa
Background/Purpose: Distinguishing Multisystem Inflammatory Syndrome in Children (MIS-C) associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) from acute, pyrexial childhood illness can be challenging.…
Abstract Number: 0259 • ACR Convergence 2021
JIA Diagnoses and Trends from 2006-2019: Has the U.S. ICD-9-to-ICD-10 Transition Created Coding Artifacts?
Daniel Horton¹, Lauren Parlett², Cecilia Huang³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard⁶, Carlos Rose⁷, Kevin Haynes² and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Institute for Health, New Brunswick, NJ, ⁴Rutgers School of Social Work, New Brunswick, NJ, ⁵Rutgers School of Public Health, New Brunswick, NJ, ⁶Ernst Mario School of Pharmacy, New Brunswick, NJ, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: JIA is the most common rheumatic disease of childhood, but recent data on diagnostic trends in the US are lacking. Furthermore, the impact of…
Abstract Number: 0773 • ACR Convergence 2021
Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Ly-Lan Bergeron², Samantha Dill², MIchelle O'Brien², Xiaobai Li³, Jomy George³, April Brundidge², Michelle Millwood², Lisa Rider⁴ and Robert Colbert⁵, ¹Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, ²Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH/NIAMS, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].